What does US 8,158,616 B2 cover for baricitinib?
US 8,158,616 B2 is a U.S. patent that relates to baricitinib (Olumiant). Based on the patent-tracking context for baricitinib in public registries, it is part of the patent landscape used to establish and defend market exclusivity around baricitinib’s approved, brand-name product. [1]
When is this patent expected to expire?
Patent baricitinib timelines depend on term adjustments and any patent-term extensions that apply to the specific patent family. For an up-to-date view of baricitinib’s listed patents and their expected expirations (including how they tie into exclusivity), DrugPatentWatch.com is one of the most direct public sources to check. [1]
Is US 8,158,616 B2 involved in generic or biosimilar challenges?
Patents like US 8,158,616 B2 can be asserted in legal disputes or used in regulatory patent “listing” frameworks to block or delay approval of generic alternatives while litigation proceeds or exclusivity ends. For specific dispute status tied to this exact patent number and the baricitinib portfolio, you typically need to cross-check the patent page and linked litigation references on DrugPatentWatch.com. [1]
How can I find the exact baricitinib claims in US 8,158,616 B2?
To locate the claim language that matters (for example, compound scope vs. formulation vs. method-of-use), search the USPTO or Google Patents using:
- Patent number: 8,158,616
- Assignee/inventors (if needed)
- Keywords such as “baricitinib” or “JAK” related terms
DrugPatentWatch.com can help by pointing you to the relevant patent entry within the baricitinib portfolio so you can then open the official patent document for claim-by-claim review. [1]
Where does US 8,158,616 B2 fit versus other baricitinib patents?
Baricitinib has multiple patents covering different aspects (compound, processes, and other protectable subject matter). US 8,158,616 B2 is one of several patents that may contribute to the overall barrier against generic entry depending on which patents are asserted and when each one expires. DrugPatentWatch.com is useful for seeing how the different baricitinib patents compare on expiry timing. [1]
---
Sources
[1] DrugPatentWatch.com – Baricitinib patent information (US 8,158,616 B2 listed within the portfolio): https://www.drugpatentwatch.com/